PRL-3在前列腺癌组织中的表达及其意义  

Expression and significance of PRL-3 in prostatic carcinoma tissues

作　　者：赵易[1] 武国军[1] 张瑞[2] 沈岚[2] 于垂恭[1] 王映梅[3] 药立波[2] 袁建林[1] 

机构地区：[1]第四军医大学西京医院泌尿外科,西安市710032 [2]第四军医大学基础部生物化学与分子生物教研室,西安市710032 [3]第四军医大学西京医院病理科,西安市710032

出　　处：《实用医学杂志》2010年第1期39-41,共3页The Journal of Practical Medicine

基　　金：国家自然科学基金资助项目(编号:30872583)

摘　　要：目的:研究蛋白酪氨酸磷酸酶PRL-3在前列腺癌及前列腺癌旁增生组织中的表达及其与临床病理特征和生物学行为的关系。方法:采用免疫组织化学S-P法检测60例前列腺石蜡包埋组织中PRL-3的表达情况,其中前列腺增生组织12例,前列腺癌组织48例,均为存档石蜡切片。并应用χ2检验方法分析PRL-3在前列腺癌组织中表达的意义与临床病理特征之间的关系。结果:免疫组化结果显示PRL-3表达定位于前列腺癌组织的细胞浆,癌组织与癌旁增生组织的阳性率为分别为79.2%和25.0%(P<0.05),癌组织中PRL-3的表达明显高于癌旁增生组织。PRL-3表达水平在不同年龄段、有无家族史之间差异无显著性(P>0.05),在不同Gleason评分之间差异有显著性(P<0.05),在不同临床TNM分期之间差异无显著性(P>0.05),在血清PSA浓度≤20ng/mL与PSA浓度>20ng/mL组间差异无显著性(P>0.05)。结论:PRL-3的表达与前列腺癌发生发展机制关系较密切,PRL-3蛋白可作为前列腺癌诊断、治疗及预后判断过程中的一种较有价值的病理学指标。Objective To study the expression of protein tyrosine phosphatase PRL-3 and to investigate its clinical, pathological and biological behavior implications in prostatic carcinoma. Methods The expression of PRL-3 was examined in 60 paraffin-embedded tissue sections including 48 cases of prostatic carcinoma and 12 cases of benign prostate hyperplasia by immunohistochemical staining. The relationship between PRL-3 expression and clinicopathological features was analyzed by Chi-square test. Results The immunoreactive staining was located in the cytoplasm of prostatic carcinoma. The positive rate of PRL-3 in prostatic carcinoma was 79.2%, which was remarkably higher than that in benign prostate hyperplasia （25.0%,P 〈 0.05）. Furthermore, the positive expression of PRL-3 in prostatic carcinoma samples increased significantly with the increasing of the Gleason score. However, the positive expression of PRL-3 was not different between ages, family medical history, stages or the concentration of prostate-specific antigen in blood serum. Conclusion PRL-3 gene plays an essential role in prostate carcinogenesis and can serve as a marker for the prognosis of prostate cancer.

关 键 词：前列腺肿瘤 PRL-3基因 良性前列腺增生 免疫组织化学 

分 类 号：R737.25[医药卫生—肿瘤] R697.32[医药卫生—临床医学]